Fintel on MSN3d
Leerink Partners Downgrades Agios Pharmaceuticals (AGIO)
Fintel reports that on September 27, 2024, Leerink Partners downgraded their outlook for Agios Pharmaceuticals (NasdaqGS:AGIO ...
Hosted on MSN14d
Leerink Partners Likes “Risk/Reward” of Immunic’s CALLIPER Readout
Leerink Partners analyst Faisal Khurshid said that he likes the “risk/reward” profile of Immunic’s CALLIPER trial readout, ...
bovnews16h
What’s Causing Ardelyx Inc (ARDX) Stock’s -8.90% Drop Over the Last Six Months?
On Friday, Ardelyx Inc (ARDX) stock saw a modest uptick, ending the day at $6.65 which represents a slight increase of $0.29 or 4.56% from the prior close of $6.36. The stock opened at $6.43 and ...
Leerink Partners Sticks to Its Buy Rating for Quanterix (QTRX)
Leerink Partners analyst Puneet Souda reiterated a Buy rating on Quanterix (QTRX – Research Report) today. The company’s shares ...
Regeneron downgraded at Leerink after Amgen’s court win; Truist defends
Regeneron (REGN) stock was downgraded by Leerink after a court ruling that favored Amgen's (AMGN) plans to introduce a biosimilar for REGN's Eylea. Read more here.
bovnews2d
The IRWD Conundrum: Why Ironwood Pharmaceuticals, Inc.’s Stock Is Making Headlines Again
On Friday, Ironwood Pharmaceuticals, Inc. (IRWD) stock saw a decline, ending the day at $4.02 which represents a decrease of $-0.04 or -0.99% from the prior close of $4.06. The stock opened at $4.15 ...
Alkermes (ALKS) Gets a Hold from Leerink Partners
In a report released on September 25, Marc Goodman from Leerink Partners maintained a Hold rating on Alkermes (ALKS – Research Report).
Business Wire19d
Xencor Announces Pricing of $175 Million Public Offering of Common Stock
Xencor, Inc. (“Xencor”) (Nasdaq: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the ...
ETF Daily News20d
Leerink Partners Initiates Coverage on MannKind (NASDAQ:MNKD)
Equities researchers at Leerink Partners initiated coverage on shares of MannKind (NASDAQ:MNKD – Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat reports ...
Investing21d
Leerink Partners sets Outperform rating on MannKind on growth avenues
Leerink Partners has initiated coverage on shares of MannKind (NASDAQ:MNKD) Corporation (NASDAQ: MNKD), assigning an Outperform rating and setting a price target of $8.00. The firm anticipates ...
Buy Rating Affirmed for enGene Holdings Amid Promising Phase 2 Results and Strategic Clinical Expansion
Leerink Partners analyst Mani Foroohar has maintained their bullish stance on ENGN stock, giving a Buy rating on September 27. Mani Foroohar ...